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Chemical stabilityAbstract Background: The prevalence of chronic diseases is increasing in Asia, therefore compli-
ance to the medications is of utmost importance to slow disease progression and improve outcomes.
Dosage administration aids (DAAs) serve as important tool to improve the compliance of patients.
However, there is a dearth of data on the stability of chronic medications in DAAs. Furthermore,
data presented by our Western counterparts may not be applicable to us because of our extreme
humidity and temperature. In this study, we aim to summarize the data available in the literature
on the stability of chronic medications in DAA.
Methods: We performed a literature search using electronic databases and related keywords.
Results: In total, 24,336 articles were retrieved and 21 articles were found to be relevant to our
topic. This commentary stratiﬁed drugs according to their treatment categories and key stability
conclusions, DAA and conditions used and recommendations were presented.
Conclusion: Due to the lack of speciﬁc data, pharmacists have to exercise their professional judg-
ment with the help from professional guidelines when using DAA in repackaging medication. Man-
ufacturers and regulators can play a greater role in ﬁlling the gap needed to provide pharmacists
with necessary information to fulﬁll their function.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.Contents
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Prevalence of chronic diseases is rising in Asia and compliance
to medication is necessary to ensure slowing of disease progres-
sion as well as improving healthcare outcomes (Tan, 2011). In
Asia, the number of people needing dosage administration aid
(DAA) to assist in medication administration is increasing
(Brown and Bussell, 2011). Reminder packaging, dosette, do-
set, multi-compartment compliance aids (MCAA) or compli-
ance aid all refer to DAA. DAA is deﬁned as a device that
assists patients in managing their medicines by having patients,
caregivers, or pharmacists, to arrange individual doses accord-
ing to their prescribed dose regime throughout the day for cer-
tain duration of time. There were many studies that had shown
favorable outcomes when patients used DAA to help them im-
prove their adherence to medications (Rivers, 1992). Studies
had shown that DAA helped to reduce medication error rates
during medication administration in nursing homes, useful to
simplify patients’ medication regime and may overcome barri-
ers to adherence such as difﬁculties in reading pharmacy labels
and opening medication containers (Roughead et al., 2003;
Cramer, 1998; Kippen et al., 2005; van Eijken et al., 2003).
There were reports showing that DAA use helps to improve
clinical outcomes like glycemic, blood pressure and lipids con-
trol (Simmons et al., 2000; Lee et al., 2006).
In Asia, especially Singapore, the weather is extremely hu-
mid and of high temperature all year round. An average rela-
tive humidity (RH) in Singapore can range from 80% to
100%, while temperature ranges from 25 to 30 C (Pinto
et al., 2011). World Health Organization’s stability guidelines
stated that certain Asian countries have long-term stability
conditions of 30 C and 75% RH (Bott and Oliveira, 2007).
This differs greatly from the conditions of the Western coun-
tries and therefore, may need a different set of stability data
so that pharmacists can determine if a particular drug will be
suitable to be stored in a DAA. Repackaging of a medicine re-
quires removal from its primary packaging, thus invalidates
the stability guarantee by the manufacturer. Manufacturers
also tend to discourage repackaging because there is little data
to support this action (Church and Smith, 2006). As far as we
know, there are very limited studies on the stability of drugs
when repackaged into a unit dosing system and this is espe-
cially so in the context of Asia. With the increase in the prev-
alence of chronic diseases in Asia, data for repackaging of
medicine into DAA will be essential so that the medicine man-
ufactured will be of suitable physical, chemical and photo
stabilities.Therefore, the aim of this commentary is to provide readers
a summary of the types of stability data available. Manufac-
turers and regulators, especially that of Asian countries, will
be able to conduct more region speciﬁc stability studies to ﬁll
the gap needed to provide the pharmacists with essential data
to support their operations. In turn, the patients’ compliance
can be improved, disease progression can be slowed and im-
proved healthcare outcomes can be delivered.
2. Methods
An electronic database search was performed using Pubmed,
Google Scholar, Web of Science, Scopus and ScienceDirect.
Hand searches were also conducted using the references of re-
lated articles. Searches were current as of June 2013. The key-
words utilized were (‘‘dosage administration aid’’ OR
‘‘reminder packaging’’ OR dosette OR doset OR repackaged
OR ‘‘compliance aid’’) AND (stability OR duration OR char-
acteristics OR degradation OR ‘‘color changes’’). There were
no exclusion criteria due to the dearth of literature on the topic
and all related articles were reviewed.
3. Results
3.1. Search results
A total of 24,336 articles were retrieved from our searches.
Twenty-one articles were found to be relevant to our topic.
3.2. Cardiovascular medications
Studies were found for 4 cardiovascular drugs, namely meto-
prolol, atenolol, frusemide and aspirin. A summary can be
found in Table 1.
Metoprolol is a beta-blocker used to treat several diseases
of the cardiovascular system such as hypertension. From the
study published by Yang et al., controlled and accelerated
test conditions are 25 C/60% RH and 40 C/75% RH,
respectively. The DAA of interest was the United States
Pharmacopoeia (USP) Class A unit dose blister pack. Tablets
were stored at accelerated and controlled conditions for
52 weeks and 12 weeks respectively. USP standards for
chemical stability were met for all conditions and packaging.
However, water uptake and tablet hardness increased for
repackaged tablets stored in accelerated conditions (Yang
et al., 2010).
Stability of chronic medicines in dosage administration aids 23The next drug of concern is Atenolol, which is another beta-
blocker. From the study published by Chan et al., the tablets
were stored at different containers and subjected to 4 storage
conditions. They were stored for 4 weeks in the original blister
pack at controlled condition, in 28 chambers plastic MCCA in
both controlled and accelerated conditions and in petri dish at
controlled conditions. Results showed that USP standards for
chemical stability were met for all packaging and storage
conditions. However, changes were observed in disintegration,
dissolution and physical appearance for the MCCA at acceler-
ated conditions. Therefore, the authors recommended that
DAA might not be suitable for countries with hot and humid
conditions (Chan et al., 2007). In another study atenolol was
investigated on, 2 different atenolol brands co-stored with aspi-
rin at controlled and accelerated conditions using opaque and
transparent DAA. The DAA of interest was Dosett Maxi
and Medidos. Results showed that USP standards for chemi-
cal stability were met for all storage and packaging conditions.
However, changes in tablet hardness were observed in a partic-
ular brand of atenolol in controlled conditions with higher
changes in the transparentDAA.Also, co-storage at accelerated
conditions resulted in non-coated aspirin tablets had a change in
appearance. Therefore, the authors concluded that multi-facto-
rial experimental conditions, such as brand of the drug, type of
DAA used and co-storage in different storage conditions might
affect the physical stability of the drug (Donyai, 2010).
Frusemide is a diuretic that is used for symptomatic relief in
ﬂuid overload patients. There were 2 studies retrieved that had
done stability studies inDAA for frusemide. One studywas con-
ducted byAsafu-Adjaye et al. with frusemide being stored in the
original high-density polyethylene (HDPE) bottle and USP
Class A unit dose blister pack at both controlled and accelerated
conditions. Tablets were stored for 52 weeks at controlled con-
ditions and 12 weeks at accelerated conditions. Results showed
that chemical stability was met for all packaging and storage
conditions. In terms of physical stability, there were no differ-
ences seen for loss on drying and dissolution rates and no change
in tablet hardness across all conditions. Therewas also no differ-
ence in the physical appearance of the tablets and no discolor-
ation was observed for both the original and repackaged
product stored in different conditions. However, the authors
concluded that these results were only applicable to tablets using
low moisture excipients, such as magnesium stearate, lactose
monohydrate and corn starch, and cannot be generalized to tab-
lets using hygroscopic excipients (Asafu-Adjaye et al., 2011).
Another study involving frusemide used Webster-Pak as
DAAof interest. The repackaged tablets were stored for 8 weeks
at controlled conditions while protected from light or at home
conditions exposed to either a standard 60 W tungsten light bulb
with indoor indirect daylight or at pharmacy conditions exposed
to a ﬂuorescent lighting with indoor indirect sunlight. Results
showed that chemical and physical stabilities were conﬁrmed
at all storage conditions. However, progressive yellow discolor-
ation was observed when stored in the simulated pharmacy con-
ditions. Therefore authors had proposed that repackaged
tablets should be protected from light by placing in a light-pro-
tecting sleeve (Bowen et al., 2007).
Aspirin is an antiplatelet used in many cardiovascular dis-
eases as a primary or secondary prevention medication. There
were 2 studies retrieved regarding stability studies of aspirin in
DAA. One study by Mylrea et al. used halved tablets of aspirin
stored in controlled, accelerated, natural variations in daylightexposure and internal temperature ﬂuctuations (23–26 C at
45–-60% RH) and refrigerated conditions (8 to 2 C) in do-
sette boxes for 1 week. Aspirin content did not meet the British
Pharmacopoeia (BP) standards for the accelerated condition
and physical appearance compromised for tablets stored in do-
sette boxes and in accelerated conditions. Also, when split tab-
lets were used, the degradation of aspirin was comparable to
the whole tablet (Mylrea et al., 2012) Another study by Yama-
zaki et al. used experimental conditions of 27 C with 55% RH
or 65% RH in a unit dose packing for 12 weeks. Results
showed that color changes occur at 65% RH and the color
change and rate of decomposition become higher as time
passed. Therefore, authors concluded that maintenance of
RH to 55% or less by storing in a plastic or aluminum pack
with drying agent may be needed to maintain the quality of
product (Yamazaki et al., 2010).3.3. Central nervous system medications
Studies were found for 4 neurological drugs, namely gabapen-
tin, clozapine, carbamazepine and sodium valproate. A sum-
mary can be found in Table 2.
Gabapentin is used as an adjunct for seizures as well as for
neuralgia management. A study by Gupta et al. that used con-
trolled and accelerated conditions at 52 and 13 weeks respec-
tively had shown that repackaged drug in a unit dose blister
pack stored under both conditions showed signiﬁcant increase
in weight. There was no signiﬁcant difference in terms of po-
tency and level of degradation between the original and
repackaged units. The authors concluded that Gabapentin in
the original bottle and repackaged blister were stable up to
one year under long term storage conditions and up to
3 months under accelerated conditions (Gupta et al., 2009).
Clozapine is an antipsychotic drug and is commonly used in
the treatment of schizophrenia. Perks et al. conducted a study
to investigate the stability of clozapine repackaged into Web-
ster-Pak at controlled and accelerated conditions for
12 weeks. Results showed that clozapine was physically and
chemically stable for up to 6 weeks with no discoloration ob-
served (Perks et al., 2012).
Carbamazepine is an anti-epilepsy and mood-stabilizing
drug. A study by al-Zein et al. compared carbamazepine of dif-
ferent brands at varying conditions. Tegretol and Tegral
were stored at 40, 50, and 60 C at 75% RH for 6, 3 and
1 month(s), respectively. Tegretol and Tegral tablets were
also removed from the orginal strip package and then placed
into bottles. The tablets were then exposed to conditions of
97% RH at 40 C for 5 min daily. The other brand, Finlepsin
was stored in a bottle and the bottle was opened to expose the
tablets for 5 min daily at 40 Cor 25 Cat 97%RH for 1 month.
Results showed that USP standards for chemical stability were
met for all packaging and storage conditions. Changes in disso-
lution rate were observed for Tegral and Finlepsin brands
but not for Tegretol brand. Therefore, the authors concluded
that the effect of storage was largely formulation dependent
with factors such as sensitivity to moisture of different excipi-
ents may play a role in tablet performance (Al-Zein et al., 1999).
Another anti-epileptic medication that was investigated on
was sodium valproate. A study conducted by Llewelyn et al.
compared controlled and accelerated conditions for a
heat-sealed DAA for 56 days. Results showed that chemical
Table 1 Summary of cardiovascular drugs’ stability in dosage administration aids.
Drug DAA Conditions (weeks) Conclusions for stability Recommendations References
Metoprolol tartrate USP Class A unit dose
blister pack
Controlled (52)
Accelerated (12)
 USP standards for chemical stability met
for all packaging and storage conditions
 Water uptake and tablet hardness
increased for repackaged tablets
stored in accelerated conditions
NA Yang and et al.
(2010)
Frusemide USP Class A unit dose
blister pack
Controlled (52)
Accelerated (12)
 USP standards for chemical stability
met for all packaging and storage conditions
 No change for loss on drying, tablet
hardness and dissolution rates for all
packaging and storage conditions
 Increase in tablet hardness for repackaged
tablets stored in accelerated conditions
Results can only be extrapolated
to non-hygroscopic excipients.
Asafu-Adjaye
and et al. (2011)
Webster-Pak Control; Home;
Pharmacy (8)
 Physical and chemical stabilities were
conﬁrmed for all storage conditions
 Progressive yellow discoloration was observed
for the tablets stored in the simulated pharmacy
condition, starting from week 1
Frusemide tablets repackaged
into DAA should be protected
from light in the pharmacy and in
patients’ homes by placing the DAA
into a light-protecting sleeve and/or
stored away from light.
Bowen and
et al. (2007)
Atenolol 28 chamber plastic MCAA Controlled;
Accelerated (4)
 USP standards for chemical stability met for
all packaging and storage conditions
 Changes in disintegration, dissolution and
physical appearance were observed for the
plastic MCAA at accelerated conditions
Certain formulation of atenolol
tablets is not suitable for storage
in hotter, humid weather
Chan and
et al. (2007)
Atenolol (2 diﬀerent brands)
co-storage with aspirin
Dosett Maxi,
Medidos
Controlled;
Accelerated (4)
 USP standards for chemical stability met for
all packaging and storage conditions
 Changes in tablet hardness in controlled
conditions were observed for Alpharma, with
storage in Dosett exerting a greater impact
than storage in Medidos
 Co-storage at elevated temperature and humidity
also impacted on the appearance of non-coated
aspirin tablets
Multi-factorial experimental
conditions impacted diﬀerently on
the physical stability of tablets stored
within MCCAs
Donyai (2010)
Aspirin Dosette boxes Controlled; accelerated;
In use condition;
Refrigerated (1)
 Only in accelerated storage condition, the
aspirin content did not meet BP speciﬁcations
 The split tablets did not display any additional
aspirin degradation when compared to the whole
tablets under the same conditions
 Physical appearance compromised for dosette boxes
and accelerated conditions
NA Mylrea and
et al. (2012)
Unit dose packing 27C/55% RH;
27 C /65% RH (12)
 Prevents color changes and preserves the quality by
maintaining the humidity as 55%
 It was revealed that the color changes became
greater and the decomposition rate became
higher as time passed
To maintain the humidity as
55% or less and storage with drying
agent in a plastic or aluminum pack
Yamazaki
and et al.
(2010)
Abbreviations: Relative humidity (RH), United States Pharmacopoeia (USP), British Pharmacopoeia (BP), multi-compartment compliance aid (MCAA), dosage administration aid (DAA), nonapplicable
(NA). Conditions: controlled (25 C /60% RH), accelerated (40 C/75% RH), in use (23–26 C/45–60% RH), refrigerated (2–8 C).
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Table 2 Summary of central nervous system drugs’ stability in dosage administration aids.
Drug DAA Conditions (weeks) Conclusions for stability Recommendations References
Clozapine Webster-Pak Controlled;
accelerated (12)
 Chemically and physically stable for
up to 6 weeks
 Discoloration of tablet not observed
NA Perks and et al. (2012)
Carbamazepine of
diﬀerent brands
Glass bottle 40 C/97% RH (4)  USP standards for chemical stability
met for all packaging and storage
conditions
 Changes in the dissolution rate were
observed for the Tegral and Finlepsin
but not Tegretol brand
Eﬀect of storage is argely formulation
dependent with fac rs such as sensitivity
to moisture of diﬀe ent excipients used
and the moisture c ntent
Al-Zein et al. (1999)
Gabapentin Unit dose blister
strips
Controlled (52)
Accelerated (13)
 Repackaged drug product stored under
all conditions showed signiﬁcant
increase in weight
 No signiﬁcant differences in potency
between the original and repackaged
drug products were detected
 Lactam degradation product levels were
within the acceptable level for all storage
conditions
NA Gupta and et al. (2009)
Sodium valporate Heat sealed DAA Controlled;
accelerated;
refrigerated
(56 days)
 Chemical stability observed at all the
storage conditions
 Variation in weight observed in
accelerated conditions
 Variation in dissolution observed for all
storage conditions
Since tablets stored in compliance aid
may be exposed to ncontrolled temp and
humidity during us in patients’ home, it is
inappropriate to re ackage sodium valporate
in a DAA
Mangan and et al. (2006)
Abbreviations: Relative humidity (RH), multi-compartment compliance aid (MCAA), dosage administration aid (DAA), non-applicable (N ). Conditions: controlled (25 C/60% RH), accelerated
(40 C/75% RH), refrigerated (2–8 C).
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Table 3 Summary of other drugs’ stability in dosage administration aids.
Drug DAA Conditions (weeks) Conclusions for stability Recommendations References
Mesalazine Polyethylene laminated
cellophane and glassine ﬁlms
Controlled; refrigerated (4)  1% weight increase of the mesalazine
tablets in controlled conditions
 Changes in color occur in
controlled conditions
Meselazine CR is not recommended for
repackaging in one dose packaging due
to discoloration and absorption of moisture
Harada and
et al. (1999)
Mebeverine,
mesalazine,
sulphasalazine,
dispersible aspirin
Venalink Monitored
System
Protected from light
and heat (5)
 The 4 medicines remain stable
in the Venalink blister packs for
at least 5 weeks.
During normal handling, rupture of
remaining tabs results in increased level
of air and humidity. Advise patient to be
careful when handling the blister pack and
to store away from heat, light and humidity
Elmasry and
et al. (2011)
Prochlorperazine Webster-Pak Controlled; accelerated;
in-use conditions
with ﬂuorescent light;
in situ conditions
with indirect daylight (8)
 BP standards were met for
chemical and physical stabilities
in all storage conditions
 Progressive gray discoloration
of the tablet observed from week 2
Photodegradants may potentially lead to
adverse eﬀect. Pharmacists need patients to
store it away from light, heat and humidity
Glass and
et al. (2009)
Paracetamol Webster-Pak Controlled; accelerated (12)  BP standards were met for
chemical and physical stabilities
in all storage conditions
Repackaged paracetamol oﬀers suﬃcient
protection against moisture and will remain
stable for a reasonable period in use of
approximately 6 weeks
Mangan and
et al. (2006)
Abbreviations: Relative humidity (RH), multi-compartment compliance aid (MCAA), dosage administration aid (DAA), British Pharmacopoeia (BP). Conditions: controlled (25 C/60% RH),
accelerated (40 C/75% RH), in use/in situ (23–26 C/45–60% RH), refrigerated (2–8 C).
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Step 1: Select an appropriate dosage 
administration aid (DAA) and drugs for 
packing
Step 2: Protect DAA from light 
Step 3: Careful removal of tablets from 
original blister and DAA 
Step 4: Careful monitoring of DAA usage 
Stability of chronic medicines in dosage administration aids 27stability was observed at all storage conditions. However, there
was a variation in weight for accelerated conditions and a var-
iation in dissolution for all storage conditions. Therefore, the
authors recommended that it was inappropriate to repackage
sodium valproate in a DAA.
3.4. Other medications
Studies were found for 5 other medications, namely mesal-
azine, mebeverine, sulphasalazine, prochlorperazine and para-
cetamol. A summary can be found in Table 3.
Mangan et al. investigated on paracetamol, a commonly
used drug over the counter pain medication. In the study,
Webster-Pak was the DAA of choice and the storage dura-
tion was 3 months. Results showed that repackaged paraceta-
mol met BP standards for chemical and physical stabilities for
both controlled and accelerated conditions. From their analy-
sis, the author recommended that paracetamol is suitable for
repackaging into a DAA for approximately 6 weeks (Mangan
et al., 2006).
Prochlorperazine is an anti-emetic, usually used for the
treatment of severe nausea and vomiting. A study by Glass
et al. that used multi-dose Webster-Pak as the DAA at con-
trolled, accelerated, under ﬂuorescent light and indirect day
light for 8 weeks had shown that BP standards for chemical
and physical stabilities were met for all storage conditions.
However, progressive graying of the tablets was observed from
week 2 onwards. Therefore, the authors recommended phar-
macists to be wary of adverse effect from photodegradants
and to protect the tablets from light, heat and humidity (Glass
et al., 2009).
Mesalazine is an anti-inﬂammatory drug for treating ulcer-
ative colitis. A study by Harada et al. used polyethylene lami-
nated cellophane and glassine ﬁlms as the container. They were
stored in room conditions (22–-25 C at 50–70% RH with 350
lux ﬂuorescence white light for 12 h or in darkness) and control
(4 C at 29% RH) for 4 weeks. Results showed that 1% weight
increase in Mesalazine tablets were seen in room conditions
accompanied by changes in color. The authors therefore con-
cluded that the tablets were not appropriate for repackaging
(Harada et al., 1999).
The last study done by Elmasry et al. involved co-storing
mebeverine, mesalazine, sulphasalazine and aspirin together
and assessing their stability. The Venalink Monitored System
was used as the DAA and protected from heat and light for
5 weeks. Results showed that the 4 medications remain stable
for up to 5 weeks in this DAA. However, the authors cau-
tioned that the handling method might cause rupture of blister
seals; affecting humidity and performance of tablet, therefore
advised counseling for patients to help them better manage
DAA (Elmasry et al., 2011).Step 5: Careful storage of DAA 
Step 6: Counsel patients on storage and 
handling of DAA 
Figure 1 Steps to guide a pharmacist on how to handle cases
involving repackaging of drugs into DAA.4. Discussion
4.1. Chemical stability
From the studies retrieved, only 1 study showed chemical sta-
bility to be affected by repackaging in DAA. However, as not
much had been done in this ﬁeld, we cannot determine the ex-
act extent and the clinical impact of chemical instability of
chronic medications when repackaged into DAA.4.2. Physical stability
From the studies retrieved, 7 studies indicated physical insta-
bility when drugs were repackaged into DAA. It was observed
in some studies that an increase in moisture absorption could
in turn lead to an increase in tablet hardness. The implications
of increased tablet hardness are decreased dissolution and this
affects the bioavailability of the medication. However, we are
unable to conclude that repackaged medications stored in
accelerated conditions will experience an increase in moisture
absorption that will affect the tablet integrity. Physical stability
is affected by multiple factors and some important factors to
consider is the excipients that are used in the manufacture of
the tablet, the moisture barrier properties of the storage device.
Exploration into the type and amount of hygroscopic excipi-
ents used, type of DAA used, storage and handling conditions
should be taken into account when deciding if a drug should be
repackaged into DAA.
4.3. Recommendations for manufacturers and regulators
From the results of this literature search, it is evident that data
on drug stability in DAA is clearly lacking in Asia. With the
extreme humidity and temperature compared to our Western
counterparts, we hope that all manufacturers, generic and
branded, can allocate some resources so that stability data
can be obtained and compliance to their medication can be
improved.
Regulators in Asia can come together and request for sta-
bility data in compliance aid when drug companies seek to en-
ter the individual markets. Licenses of previously approved
drugs can be renewed only upon provision of crucial essential
stability data.
28 J.Z.Y. Tan, Y.H. Kwan4.4. Recommendations for pharmacists and patients
Pharmacists on the ground can gather information on which
are the most popular and important medications so that fo-
cused studies can be done on those drugs. Hospitals should
also come up with algorithms to guide pharmacists on how
to select drugs to pack into DAA so as to maintain the stability
of the medication. One algorithm that was proposed with the
Australia Professional Practice Guideline in mind is shown
in Fig. 1 (Australia PSo, 2010). Step 1 will be to select an
appropriate DAA with appropriate permeability for the envi-
ronment. There should also be considerations on whether the
drugs being repackaged will be stable for the DAA. Step 2 will
be to protect the DAA repackaged with medicine from light in
the pharmacy or patients’ house to maintain photo stability.
This can be done by putting in suitable light-protecting sleeves
such as black bags or foils. Step 3 involves careful removal of
tablets from blister to prevent neighboring blisters from rup-
turing. Step 4 involves careful monitoring of the DAA packag-
ing from repackaging, dispensing and when patient is using it.
Step 5 involves choosing an appropriate location to store the
product to minimize heat, humidity and light exposure while
keeping away from children. Step 6 involves counseling the pa-
tient the right way of using and storing DAA.5. Conclusions
A literature search on the stability of chronic drugs in DAA
had been summarized. Manufacturers, regulators, and
researchers should seek to close the gap by conducting stability
studies on highly used and essential chronic medications in
Asia. Pharmacists should adhere to professional guidelines
and exercise their professional judgment while acknowledging
the dearth in data when packing chronic medications into
DAA.
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